Prospective Study of Patients Med Hirsutism as Primary Work Diagnose
Hirsutism is the presence of terminal hairs in a male-like pattern in females, due to
elevated male hormone levels. Females with hirsutism are often overweight and have
metabolism disturbances as insulin resistance and impaired glucose tolerance.
The previous studies showed that patients with hirsutism (especially them with polycystic
ovarian syndrome (PCOS)) have an increased risk to develop type 2 diabetes mellitus on the
background of insulin resistance / hyperinsulinemia: 30-35 % of females with PCOS had
impaired glucose tolerance and 5-10 % of them diabetes (1, 2, 3, 4). Hyperinsulinemia
increases the risk to develop dyslipidemia and cardiovascular diseases (5, 6, 7, 8, 9).
A previous study in our department who included 340 females with hirsutism (210 with
idiopathic hirsutism and 134 with PCOS) showed that 6.6% of them had diabetes and 55%
insulin resistance (10).
There were only few long-term follow up studies of patients with hirsutism concerning their
risk to develop diabetes. As far as we now, such studies on patients with idiopathic
hirsutism are not available until now.
Hirsutism is been treated with low dose oral contraceptives, which are suppressing androgen
production. This treatment can also influence the risk to develop diabetes and
atheromatosis. The previous studies showed that the low dose oral contraceptives had modest
influence on the lipid profiles and carbohydrate metabolism in patients with hirsutism, but
increased the risk to develop coronary disease (11).
- To study and quantify, in patients with hirsutime, the risk to develop type 2 diabetes
on the background of insulin resistance / decreased glucose tolerance and atheromatosis
on the background of insulin resistance / hypercholesterolemia.
- To clarify the effect of P-pills on patients hair growth and metabolism.
Design The patients who had previously included in the study between1997 – 2000 (231) will
be contacted in order to be followed. We will estimate the grad of excess hair growth, the
hormonal and metabolism profiles.
Inclusion criteria The patients which had been included in the previous study between 1997 –
2000, oral glucose tolerance test included.
Exclusion criteria Pregnancy.
Anamnesis: previous treatment, pregnancy / in-utero fertilisation history, family
predisposition to diabetes and cardiovascular diseases.
Clinical examination: Ferriman–Gallwey score, body mass index (BMI), waist / hip ratio
(WHR), blood pressure.
- Metabolism profile (oral glucose tolerance test, lipid profile);
- Hormonal profile (androgen and oestrogen levels, prolactin, FH, FSH).
The ethic aspects
We want to evaluate the effect of the treatment and how the risk factors are influenced by
All the patients will receive both oral and written information about the study. It will be
emphasised at participation is voluntary and the informed consent can be retracted at any
time and this will not influence the treatment of them.The trial is validated by the local
The project will be carried on The Endocrinology Department, Odense University Hospital,
Denmark, which will supply technical assistance. Blood analyses will be founded by private
1. Diamanti-Kandarakis, E., Baillargeon, J. P., Iuorno, M. J., Jakubowicz, D. J., and
Nestler, J. E. A modern medical quandary: polycystic ovary syndrome, insulin
resistance, and oral contraceptive pills.J.Clin.Endocrinol.Metab 2003 88 1927-1932
2. Arslanian, S. A., Lewy, V. D., and Danadian, K. Glucose intolerance in obese
adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell
dysfunction and risk of cardiovascular disease.J.Clin.Endocrinol.Metab 2001 86 66-71
3. Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., and Imperial, J.
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary
syndrome.Diabetes Care 1999 22 141-146
4. Palmert, M. R., Gordon, C. M., Kartashov, A. I., Legro, R. S., Emans, S. J., and
Dunaif, A. Screening for abnormal glucose tolerance in adolescents with polycystic
ovary syndrome.J.Clin.Endocrinol.Metab 2002 87 1017-1023
5. Elting, M. W., Korsen, T. J., Bezemer, P. D., and Schoemaker, J. Prevalence of diabetes
mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS
population.Hum.Reprod. 2001 16 556-560
6. Loucks, T. L., Talbott, E. O., McHugh, K. P., Keelan, M., Berga, S. L., and Guzick, D.
S. Do polycystic-appearing ovaries affect the risk of cardiovascular disease among
women with polycystic ovary syndrome?Fertil.Steril. 2000 74 547-552
7. Mather, K. J., Kwan, F., and Corenblum, B. Hyperinsulinemia in polycystic ovary
syndrome correlates with increased cardiovascular risk independent of
obesity.Fertil.Steril. 2000 73 150-156
8. Vrbikova, J., Cifkova, R., Jirkovska, A., Lanska, V., Platilova, H., Zamrazil, V., and
Starka, L. Cardiovascular risk factors in young Czech females with polycystic ovary
syndrome.Hum.Reprod. 2003 18 980-984
9. Wild, S., Pierpoint, T., McKeigue, P., and Jacobs, H. Cardiovascular disease in women
with polycystic ovary syndrome at long-term follow-up: a retrospective cohort
study.Clin.Endocrinol.(Oxf) 2000 52 595-600
10. Glintborg, D., Henriksen, J. E., Andersen, M., Hagen, C., Hangaard, J., Rasmussen, P.
E., Schousboe, K., and Hermann, A. P. Prevalence of endocrine diseases and abnormal
glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the
referral diagnosis.Fertil.Steril. 2004 82 1570-1579
11. Creatsas, G., Koliopoulos, C., and Mastorakos, G. Combined oral contraceptive treatment
of adolescent girls with polycystic ovary syndrome. Lipid profile.Ann.N.Y.Acad.Sci.
2000 900 245-252
Observational Model: Case Control, Observational Model: Natural History, Time Perspective: Longitudinal, Time Perspective: Prospective
Magdalena Andries, MD
Odense University Hospital
Denmark: National Board of Health